RxDoctor Payments Data

Cornelius Mance, MD

Neurology · Hixson, TNNPI 1861586331

Payments from drug & device makers

$17,342in general payments, 2019–2025

Across 876 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Neurocrine Biosciences, Inc.$1K
  • Biogen$1K
  • AbbVie$985
  • UCB, Inc.$834
  • plus $11K from 54 others

What the payments were for

  • Food & beverage$17,23099%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen(2 entities)43$1,360
Teva Pharmaceuticals USA, Inc.60$1,260
Neurocrine Biosciences, Inc.54$1,134
Biogen59$1,104
AbbVie(2 entities)68$985
UCB, Inc.35$834
Acadia Pharmaceuticals Inc46$766
Lilly USA, LLC34$731
AstraZeneca(2 entities)23$584
Eisai Inc.29$562
Novartis28$549
Bristol Myers Squibb29$525
Avanir Pharmaceuticals, Inc.42$497
Neurelis, Inc.22$471
Lundbeck LLC23$460
Sanofi19$457
Otsuka America Pharmaceutical, Inc.19$422
EMD Serono, Inc.19$392
Argenx US, Inc.18$388
Pfizer20$377
Sunovion Pharmaceuticals Inc.18$325
Biohaven Pharmaceuticals, Inc.16$256
Supernus Pharmaceuticals, Inc.22$252
Genentech USA, Inc.12$249
Biohaven Pharmaceutical Holding Company Ltd.11$241
Johnson & Johnson(2 entities)12$224
Upsher-smith Laboratories LLC12$224
SK Life Science, Inc.9$194
E.r. Squibb & Sons, L.L.C.9$173
Kyowa Kirin, Inc.4$142
Banner Life Sciences, LLC7$142
Mallinckrodt Hospital Products Inc.4$110
Jazz Pharmaceuticals Inc.4$76
Adamas Pharmaceuticals, Inc.4$73
Corium, LLC3$66
CSL Behring3$62
Mallinckrodt Enterprises LLC3$60
TG Therapeutics, Inc.3$54
Grifols USA, LLC2$43
Arbor Pharmaceuticals, Inc.3$40
Boston Scientific2$39
Catalyst Pharmaceuticals, Inc.2$38
Zyla Life Sciences, Inc.2$35
Amneal Pharmaceuticals LLC2$35
Axsome Therapeutics, Inc.1$32
Promius Pharma LLC2$29
Harmony Biosciences LLC1$27
Ipsen Biopharmaceuticals, Inc1$25
Cycle Pharmaceuticals Inc1$23
Avion Pharmaceuticals1$21
Vanda Pharmaceuticals Inc.1$20
MDD US Operations, LLC1$19
Tanabe Pharma America, Inc.1$19
Merck1$18
Nevro Corp.1$18
Alfasigma USA, Inc.1$18
Inspire Medical Systems, Inc.1$17
Sanofi-aventis U.S. LLC1$15
Sumitomo Pharma America, Inc.1$14
Greenwich Biosciences, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,342 in reported general payments places this provider in the 65th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$111,434
Medicare patients
413
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate12$237,382
AustedoDeutetrabenazine12$168,274
HizentraImmun Glob G(Igg)/Pro/Iga 0-5013$145,894
Kesimpta PenOfatumumab13$138,917
AubagioTeriflunomide14$128,631
NuplazidPimavanserin Tartrate17$83,113
BriviactBrivaracetam41$80,946
FycompaPerampanel39$48,669
NuedextaDextromethorphan Hbr/Quinidine25$36,697
Emgality PenGalcanezumab-Gnlm22$14,510
NeuproRotigotine13$10,140
Lacosamide42$9,165
BrilintaTicagrelor14$8,888
Oxtellar XrOxcarbazepine11$6,368
Rasagiline Mesylate13$4,057

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$1,260$168,27412 claims
CSL BehringHizentra$62$145,89413 claims
SanofiAubagio$457$128,63114 claims
UCB, Inc.Briviact, Neupro$834$91,08654 claims
Acadia Pharmaceuticals IncNuplazid$766$83,11317 claims
Eisai Inc.Fycompa$562$48,66939 claims
Avanir Pharmaceuticals, Inc.Nuedexta$497$36,69725 claims
AstraZenecaBrilinta$584$8,88814 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$252$6,36811 claims
Upsher-smith Laboratories LLCTopiramate$224$1,67295 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 361 neurology providers in Tennessee.

Other neurology in Hixson

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →